<p><strong>Pediatric Use</strong>: The safety and efficacy of Obinutuzumab in children below 18 years of age have not been established.<br />
<br />
Geriatric Use:</p>

<ul>
	<li><strong>Chronic Lymphocytic Leukemia (CLL)</strong>: In the pivotal study in CLL, 46% (156 out of 336) of patients treated with Obinutuzumab plus chlorambucil were 75 years old or older (median age was 74 years). These patients experienced more serious adverse events and adverse events leading to death than patients &lt;75 years of age. No significant differences in efficacy were observed between patients &ge;75 years of age and those &lt;75 years of age</li>
	<li><strong>Non-Hodgkin Lymphoma (NHL)</strong>: In the pivotal studies in NHL, patients 65 years old or older experienced more serious adverse events, and adverse events leading to withdrawal or death than patients &lt;65 years of age. No clinically meaningful differences in efficacy were observed.</li>
</ul>